Unknown

Dataset Information

0

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.


ABSTRACT:

Background

No biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory retrospective analysis of a Phase 2 study, we constructed composite biomarker scores (CBSs) to predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic RCC randomised to receive lenvatinib-plus-everolimus.

Methods

Of 40 biomarkers tested, the 5 most strongly associated with PFS (HGF, MIG, IL-18BP, IL-18, ANG-2) or OS (TIMP-1, M-CSF, IL-18BP, ANG-2, VEGF) were used to make a 5-factor PFS-CBS or OS-CBS, respectively. A 2-factor CBS was generated with biomarkers common to PFS-CBS and OS-CBS. Patients were divided into groups accordingly (5-factor-CBS high: 3-5, CBS-low: 0-2; 2-factor-CBS high: 1-2, CBS-low: 0).

Results

PFS/OS with lenvatinib-plus-everolimus were significantly longer in the 5-factor CBS-high group versus the CBS-low group (P?=?0.0022/P?ConclusionsThe 5-factor CBS may identify patients with metastatic RCC who would benefit from lenvatinib-plus-everolimus versus everolimus; additional validation is required.

Clinical trial registration

The clinical trial registration number is NCT01136733.

SUBMITTER: Lee CH 

PROVIDER: S-EPMC7782770 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.

Lee Chung-Han CH   Motzer Robert J RJ   Glen Hilary H   Michaelson M D MD   Larkin James J   Minoshima Yukinori Y   Kanekiyo Michio M   Ikezawa Hiroki H   Sachdev Pallavi P   Dutcus Corina E CE   Funahashi Yasuhiro Y   Voss Martin H MH  

British journal of cancer 20201007 1


<h4>Background</h4>No biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory retrospective analysis of a Phase 2 study, we constructed composite biomarker scores (CBSs) to predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic RCC randomised to receive lenvatinib-plus-everolimus.<h4>Methods</h4>Of 40 biomarkers tested, the 5 most strongly associated with PFS (HGF, MIG, IL-18BP, IL-18, ANG-2) or OS (TI  ...[more]

Similar Datasets

| S-EPMC5791841 | biostudies-literature
| S-EPMC6400440 | biostudies-literature
| S-EPMC5507652 | biostudies-literature
| S-EPMC5578126 | biostudies-literature
| S-EPMC7415534 | biostudies-literature
| S-EPMC9164172 | biostudies-literature
| S-EPMC9254865 | biostudies-literature
| S-EPMC8385286 | biostudies-literature
| S-EPMC8740438 | biostudies-literature
| S-EPMC6175670 | biostudies-literature